Your session is about to expire
← Back to Search
Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment
N/A
Waitlist Available
Research Sponsored by Daiichi Sankyo
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This study will use real-world data to assess prevalence of brain metastases in metastatic non-small cell lung cancer (mNSCLC) patients and its impact on associated clinical outcomes.
Eligible Conditions
- Lung Cancer
- Cancer
- Brain Tumor
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
4Treatment groups
Experimental Treatment
Group I: mNSCLC - OverallExperimental Treatment1 Intervention
Participants with diagnosis of mNSCLC during study period (01/01/2015-06/30/2023)
Group II: mNSCLC - 3rd Line of TherapyExperimental Treatment1 Intervention
Participants with diagnosis of mNSCLC during study period (01/01/2015-06/30/2023) treated with systemic anti-cancer therapy in third line setting.
Group III: mNSCLC - 2nd Line of TherapyExperimental Treatment1 Intervention
Participants with diagnosis of mNSCLC during study period (01/01/2015-06/30/2023) treated with systemic anti-cancer therapy in second line setting.
Group IV: mNSCLC - 1st Line of TherapyExperimental Treatment1 Intervention
Participants with diagnosis of mNSCLC during study period (01/01/2015-06/30/2023) treated with systemic anti-cancer therapy in first line setting.
Find a Location
Who is running the clinical trial?
Daiichi SankyoLead Sponsor
423 Previous Clinical Trials
446,946 Total Patients Enrolled